智通财经网·2025-09-03 14:04Group 1 - Novartis expands collaboration with Argo Biopharma, focusing on multiple cardiovascular assets with a total deal value of up to $5.2 billion [1] - Novartis gains two options for drug candidates targeting severe hypertriglyceridemia (sHTG) and mixed dyslipidemia, allowing for development and commercialization rights outside of China [1] - After Argo completes a joint clinical trial for candidate drug BW-00112, Novartis will have priority negotiation rights for this asset [1] Group 2 - Argo Biopharma will receive an upfront payment of $160 million from Novartis, with potential milestone payments and option exercise payments totaling up to $5.2 billion [1] - Argo is also entitled to receive sales royalties based on the commercialization performance of the assets [1] - Future financing rounds may include potential equity financing support from Novartis for Argo [1]